Edward D. Kobus, President of Invado Pharmaceuticals, Joins Transdermal Delivery Solutions Corp. (TDSC) Board of Advisors
TDSC, a leader in the development of breakthrough spray-on drug
delivery systems, announced today key advisor and veteran pharma
entrepreneur to accelerate progress
PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–#HypoSpray–Transdermal Delivery Solutions Corporation (TDSC) www.TDSC.us
announced today that Edward “Ed” D. Kobus, testosterone hormone
replacement therapies veteran, has joined its Board of Advisors.
“We are very pleased to have Ed Kobus, a veteran professional and pharma
entrepreneur, join our Board of Advisors,” said Kenneth Kirby, President
of TDSC. “His years of experience with AndroGel® & Testim®, his
knowledge of Medicare and managed care reimbursement as well as his
reputation, relationships and track-record of success, validating his
record of billions in revenue from transdermal testosterone, will be an
invaluable asset to our organization moving forward as we commercialize
the Testagen® opportunity.”
Kobus was involved in the initial development of AndroGel with Unimed
Pharmaceuticals. Subsequently, he launched AndroGel as both a Regional
Sales Director and Area Business Manager in Managed Care for Solvay
Pharmaceuticals, after the acquisition of Unimed by Solvay. He
successfully negotiated a $75 million sale, the largest contract in
Solvay USA history. AndroGel’s sales under AbbVie currently exceed $1.4
Billion per year. Subsequently, he was hired by Solvay’s lead competitor
Auxilium, and as Director of National Accounts, he launched Testim,
Auxilium’s Testosterone Gel competitor and he collaborated on developing
and implementing their national Medicare Part D contract strategy and
secured 24 major formulary listings for Testim in an 18-month period.
Testim’s sales now exceed $400 million per year. Kobus subsequently
formed Invado Pharmaceuticals, developed and launched a product,
obtained substantial Medicare reimbursement and managed care listings
and successfully vended the product to Valeant Pharmaceuticals of Canada
in 2015.
Kobus has 25+ years of experience in the pharmaceutical industry
focusing on transdermal drug delivery, medical devices (implant) and
alternative therapies. He has demonstrated success in start-up and
turnaround environments, and is an acknowledged expert at accomplishing
reimbursement with Medicare Part B, CMS, PBMs, and all third party
payers. He is an entrepreneurial pharmaceutical director with proven
success in Managed Markets, Sales, Sales Management, Managed Care
Marketing and Contracting.
“I am excited to join Ken and the TDSC team and look forward to resuming
pioneering in male hormone replacement with TDSC’s paradigm-shifting
platform technology,” said Edward Kobus. “The main challenge limiting
exponential growth for the testosterone products has been the lifestyle
limitations and access to safer products. The Testagen® fast-drying
product solves all of these issues and will be attractive to
prescribers, patients and their families. Consequently, potential
partners or the company itself will be well-positioned to acquire a big
share of a market with substantial growth potential.”
About Low Testosterone
Low Testosterone or ‘Low T,’ also known as hypogonadism, is a condition
in men characterized by the body’s failure to produce normal amounts of
the hormone testosterone, a male sex hormone produced by the testes. Low
T affects nearly 14 million men in the United States; yet only 9 percent
(1.3 million) of men diagnosed with Low T are receiving treatment for
the condition. Symptoms associated with Low T include erectile
dysfunction and decreased sexual desire, fatigue, loss of energy, mood
depression, regression of secondary sexual characteristics and
osteoporosis.
About Transdermal Delivery Solutions (TDSC)
TDSC is committed to advancing the science of transdermal drug delivery
using its patented spray-on delivery system platform, HypoSpray®. TDSC’s
proprietary system enables a much larger number of medications to be
delivered directly through the skin, for systemic or localized
application, utilizing its rapid acting, patchless, spray-on technology.
TDSC’s technology represents a paradigm-shift in drug delivery. http://www.tdsc.us/lower.php?url=tdsc-platform
Video: https://www.youtube.com/watch?v=Ff-1z1SYoF8
About Hormone Replacement Technologies (HRT, Inc.)
HRT, Inc. is a subsidiary of TDSC that focuses on creating innovative,
specific and medically current solutions impacting hormone replacement
needs.
Company: Hormone Replacement Technologies, Inc.: www.HRTINC.us
Contacts
MarCom Consultant (for TDSC)
Cindy Metzler, 561-429-6429
cindy@cindymetzler.com
www.tdsc.us
